Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan for inoperable chronic thromboembolic pulmonary hypertension
NL-OMON41516Phase 2Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Macitentan 10 mg with Placebo (2 arms). Primary endpoint: Pulmonary vascular resistance at rest. Started Aug 2014; status: active, not recruiting.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NL-OMON41516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41516.